{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:48:24Z","timestamp":1771044504012,"version":"3.50.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:p>Hypertrophic cardiomyopathy (HCM) is 1 of the most frequent genetic cardiovascular diseases affecting 1 out of every 500 individuals in general population. Atrial Fibrillation incidences were 3.8% per 100 patients per year and overall prevalence among HCM patients are 27.09%. Higher risk of death noted in HCM patients with atrial fibrillation. Stroke and other thrombo embolic risks are increased in such patients. Medical management using mainly betablockers or amiodarone produced variable results and high rate of recurrence. Catheter ablation reduced symptom burden and complications despite moderate recurrence. Patients with multiple repeated procedures found to have better success rate and outcomes. The complications are not high leading to increased feasibility of the procedure. More research using latest techniques in catheter ablation need to be studied.<\/jats:p>","DOI":"10.1097\/hpc.0000000000000210","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T22:48:29Z","timestamp":1581029309000},"page":"87-89","source":"Crossref","is-referenced-by-count":6,"title":["Atrial Fibrillation in Hypertrophic Cardiomyopathy: Evidence-based Review About Mechanism, Complications and Management"],"prefix":"10.1097","volume":"19","author":[{"given":"Karuppiah","family":"Arunachalam","sequence":"first","affiliation":[{"name":"Division of Cardiology, The Warren Alpert Medical School of Brown University,Providence, Rhode Island"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Maan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony","family":"Chu","sequence":"additional","affiliation":[{"name":"Division of Cardiology, The Warren Alpert Medical School of Brown University,Providence, Rhode Island"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2169\/internalmedicine.55.6480","article-title":"Interrelationship between the myocardial mass, fibrosis, BNP, and clinical outcomes in hypertrophic cardiomyopathy.","volume":"55","author":"Miyaji","year":"2016","journal-title":"Intern Med"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"e001002","DOI":"10.1161\/JAHA.114.001002","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population.","volume":"3","author":"Siontis","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy.","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12350-008-9005-5","article-title":"Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy.","volume":"16","author":"Sciagr\u00e0","year":"2009","journal-title":"J Nucl Cardiol"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1016\/j.jacc.2016.04.026","article-title":"Stroke and bleeding risks in NOAC- and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation.","volume":"67","author":"Noseworthy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0735-1097(10)80014-2","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study.","volume":"15","author":"Robinson","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0002-9149(91)90441-M","article-title":"Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone.","volume":"67","author":"Fananapazir","year":"1991","journal-title":"Am J Cardiol"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.hrthm.2005.11.013","article-title":"Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy.","volume":"3","author":"Kilicaslan","year":"2006","journal-title":"Heart Rhythm"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/heartjnl-2016-309672","article-title":"Predictors of atrial fibrillation in hypertrophic cardiomyopathy.","volume":"103","author":"Guttmann","year":"2017","journal-title":"Heart"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.hrthm.2015.03.042","article-title":"Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy.","volume":"12","author":"Bassiouny","year":"2015","journal-title":"Heart Rhythm"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eupc.2005.05.015","article-title":"Complete pulmonary vein isolation guided by three-dimensional electroanatomical mapping for the treatment of paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy.","volume":"7","author":"Liu","year":"2005","journal-title":"Europace"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/europace\/euq013","article-title":"Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression.","volume":"12","author":"Di Donna","year":"2010","journal-title":"Europace"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jjcc.2014.07.005","article-title":"Results of catheter ablation of atrial fibrillation in hypertrophied hearts - Comparison between primary and secondary hypertrophy.","volume":"65","author":"M\u00fcssigbrodt","year":"2015","journal-title":"J Cardiol"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/CIRCEP.113.000339","article-title":"Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence.","volume":"6","author":"Santangeli","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R16-20230912","first-page":"167","article-title":"Effectiveness of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy.","volume":"3","author":"Yan","year":"2013","journal-title":"Chin J Cardiac Arrhyth"},{"key":"R17-20230912","first-page":"414","article-title":"Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy.","volume":"17","author":"Zhou","year":"2013","journal-title":"Chin J Cardiac Arrhyth"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3892\/etm.2013.1158","article-title":"Meta-analysis of the therapeutic effects of various methods for the treatment of chronic atrial fibrillation.","volume":"6","author":"Lin","year":"2013","journal-title":"Exp Ther Med"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/europace\/euv339","article-title":"Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis.","volume":"18","author":"Zhao","year":"2016","journal-title":"Europace"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jacc.2014.12.063","article-title":"Atrial fibrillation ablation in patients with hypertrophic cardiomyopathy: long-term outcomes and clinical predictors.","volume":"65","author":"Contreras-Valdes","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1540-8167.2008.01192.x","article-title":"Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy.","volume":"19","author":"Bunch","year":"2008","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.amjcard.2006.12.087","article-title":"Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy.","volume":"99","author":"Gaita","year":"2007","journal-title":"Am J Cardiol"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.amjcard.2016.08.092","article-title":"Incidence of device-detected atrial fibrillation and long-term outcomes in patients with hypertrophic cardiomyopathy.","volume":"119","author":"van Velzen","year":"2017","journal-title":"Am J Cardiol"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jce.12982","article-title":"High incidence of de novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device.","volume":"27","author":"Wilke","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10840-014-9894-y","article-title":"Left atrial wall thickness and outcomes of catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy.","volume":"40","author":"Hayashi","year":"2014","journal-title":"J Interv Card Electrophysiol"},{"key":"R26-20230912","first-page":"315","article-title":"Prolongation of QTc interval predicts atrial fibrillation recurrence after catheter ablation in patients with hypertrophic cardiomyopathy.","volume":"33","author":"Liu","year":"2014","journal-title":"J Cardiovasc Pulm Dis"},{"key":"R27-20230912","first-page":"17","article-title":"Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: atrial fibrillation type determines the success rate.","volume":"71","author":"Derejko","year":"2013","journal-title":"Kardiol Pol"},{"key":"R28-20230912","first-page":"352","article-title":"Radiofrequency catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy.","volume":"13","author":"Lu","year":"2009","journal-title":"Chin J Cardiac Arrhyth"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1253\/circj.CJ-14-0823","article-title":"Impact of left ventricular diastolic dysfunction on outcome of catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy.","volume":"79","author":"Okamatsu","year":"2015","journal-title":"Circ J"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/europace\/euq434","article-title":"Predictors of recurrence following radiofrequency ablation for persistent atrial fibrillation.","volume":"13","author":"McCready","year":"2011","journal-title":"Europace"}],"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T08:19:20Z","timestamp":1694506760000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/hpc.0000000000000210","relation":{},"ISSN":["1535-282X"],"issn-type":[{"value":"1535-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}